ACTIVE

ARKOPHARMA BELUX

Export PDF

Financial year 2024 · Closed on 31/12/2024

Net result68,9 k €-82,8 %over 1 year

Revenue8,6 M €+0,8 %over 1 year

Equity2 M €+3,6 %over 1 year

Workforce20,8 ETP-4,6 %over 1 year

Identity

Source · BCE/KBO

ARKOPHARMA BELUX is a Public limited company incorporated in 1943. Its registered office is in Wavre. It employs on average 20,8 ETP workers (FTE).

Legal situation: Normal situation
BCE/KBO no. / VAT: BE 0401.962.852
Incorporation: 23/12/1943
Legal form: Public limited company
Registered office: Avenue Edison 13
1300 Wavre · WallonieSee on map
Contributed capital: 125 000,00 €
Latest accounts: 31/12/2024
Average workforce: 20,8 ETP

Joint committees (2)

Signals

ProfitableSolid equityGood liquidityPositive cashflowPositive EBITDAHealthy social debtsHigh revenue

Financials

Source · NBB, 21 filings

Trend over 18 financial years

	2024		2023		2022		2021		2020
Income statement
Revenue	8,6 M €	+0.8%	8,5 M €	-1.5%	8,6 M €	+1.9%	8,5 M €	-4.4%	8,9 M €
EBITDA	496,3 k €	-32.9%	739,4 k €	+29.2%	572,3 k €	+7.7%	531,4 k €	+4.6%	508 k €
Operating result	256,1 k €	-54.9%	567,8 k €	+17.4%	483,6 k €	+9.4%	442,2 k €	-4.8%	464,3 k €
Net result	68,9 k €	-82.8%	399,6 k €	+38.1%	289,5 k €	+8.3%	267,3 k €	-9.6%	295,7 k €
Balance sheet
Equity	2 M €	+3.6%	1,9 M €	+26.4%	1,5 M €	+23.7%	1,2 M €	+1.4%	1,2 M €
Total assets	5,3 M €	-1.6%	5,4 M €	+12.2%	4,8 M €	+0.0%	4,8 M €	+20.7%	4 M €
Cash	136,7 k €	+57.4%	86,9 k €	-70.8%	297 k €	+32.6%	224 k €	+175%	81,4 k €
Debts	3,3 M €	-4.4%	3,4 M €	+6.0%	3,2 M €	-8.1%	3,5 M €	+30.3%	2,7 M €
Other
Workforce	20,8 ETP	-4.6%	21,8 ETP	-11.4%	24,6 ETP	+6.5%	23,1 ETP	-6.9%	24,8 ETP

Valuation

Indicative valuation

As an indication, this company is worth

between 2,5 M€ and 5 M€

See the valuation

Board of directors

Source · NBB, accounts to 31/12/2024

3 active · 50 ended

Active mandates

Olivier Ricq

Director · since 27 novembre 2023 · until 13 septembre 2026

Active

PATRICK VERBELEN

Director · since 27 novembre 2023 · until 13 septembre 2026

Active

Dermapharm

Mandate

Represented by Andreas Eberhorn

Active

Ended mandates

Dermapharm

Managing director · since 27 novembre 2023 · until 16 juin 2026

Ended

Olivier Ricq

Director · since 27 novembre 2023 · until 16 juin 2026

Ended

PATRICK VERBELEN

Director · since 27 novembre 2023 · until 16 juin 2026

Ended

Dermapharm

Managing director · since 08 mars 2023 · until 28 novembre 2023

Represented by Andreas Eberhorn

Ended

Full financial information

Source · NBB

	2024	2023	2022	2021	2020	2019
Type of account	Full model	Full model	Full model	Full model	Full model	Full model
Start of the financial year	01/01/2024	01/01/2023	01/01/2022	01/01/2021	01/01/2020	01/01/2019
Closing of the financial year	31/12/2024	31/12/2023	31/12/2022	31/12/2021	31/12/2020	31/12/2019
Length of the financial year	12 months	12 months	12 months	12 months	12 months	12 months
Filing date	14/09/2026	28/11/2025	28/11/2023	24/11/2023	11/08/2021	02/07/2020
General meeting	13/09/2026	27/11/2025	28/11/2023	24/11/2022	15/06/2021	16/06/2020
Currency of the financial year	EUR	EUR	EUR	EUR	EUR	EUR
NBB quality label	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls

Financial ratios

Source · NBB

Looking for more information about this company?

Try for 7 days

Annual accounts filings

Source · NBB, 21 filings

Model	Closing	General meeting	Filed	Language	Document
Full model	31/12/2024	13/09/2026	14/09/2026	French	PDF
Full model	31/12/2023	27/11/2025	28/11/2025	French	PDF
Full model	31/12/2022	28/11/2023	28/11/2023	French	PDF
Full modelCorrection	31/12/2021	24/11/2022	24/11/2023	French	PDF
Full model	31/12/2021	24/11/2022	14/04/2023	French	PDF
Full model	31/12/2020	15/06/2021	11/08/2021	French	PDF
Full model	31/12/2019	16/06/2020	02/07/2020	French	PDF
Full model	31/12/2018	18/06/2019	21/06/2019	French	PDF
Full model	31/12/2017	19/06/2018	06/07/2018	French	PDF
Full modelCorrection	31/12/2016	20/06/2017	23/08/2017	French	PDF
Full model	31/12/2016	20/06/2017	11/07/2017	French	PDF
Full model	31/12/2015	12/07/2016	23/08/2016	French	PDF
Full model	31/12/2014	16/06/2015	10/07/2015	French	PDF
Full model	31/12/2013	17/06/2014	10/07/2014	French	PDF
Full model	31/12/2012	18/06/2013	15/07/2013	French	PDF
Full model	31/12/2011	19/06/2012	17/07/2012	French	PDF
Full model	31/12/2010	21/06/2011	14/07/2011	French	PDF
Full model	31/12/2009	15/06/2010	13/07/2010	French	PDF
Full model	31/12/2008	16/06/2009	14/07/2009	French	PDF
Full model	31/12/2007	09/04/2008	08/05/2008	French	PDF
Full model	31/12/2006	19/06/2007	04/07/2007	French	PDF

Indicative valuation

Order of magnitude

As an indication, this company is worth

between 2,5 M€ and 5 M€

The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.

Discover the Business plan

Disclaimer

Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.

Board of directors

Source · NBB, accounts to 31/12/2024

3 active · 50 ended

Active mandates

Olivier Ricq

Director · since 27 novembre 2023 · until 13 septembre 2026

Active

PATRICK VERBELEN

Director · since 27 novembre 2023 · until 13 septembre 2026

Active

Dermapharm

Mandate

Represented by Andreas Eberhorn

Active

Ended mandates

Dermapharm

Managing director · since 27 novembre 2023 · until 16 juin 2026

Ended

Olivier Ricq

Director · since 27 novembre 2023 · until 16 juin 2026

Ended

PATRICK VERBELEN

Director · since 27 novembre 2023 · until 16 juin 2026

Ended

Dermapharm

Managing director · since 08 mars 2023 · until 28 novembre 2023

Represented by Andreas Eberhorn

Ended

Ownership and network

Looking for more information about this company?

Try for 7 days

Belgian Official Gazette publications

Source · Belgian Official Gazette

Restructuring06/03/2024
STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS, ) - RUBRIQUE RESTRUCTURATION (FUSION, SCISSION, TRANSFERT PATRIMOINE, ETC...)
PDF
Restructuring08/12/2023
RUBRIQUE RESTRUCTURATION (FUSION, SCISSION, TRANSFERT PATRIMOINE, ETC...) - DIVERS
PDF
Mandates15/12/2020
DEMISSIONS, NOMINATIONS
PDF
Mandates18/06/2020
DEMISSIONS, NOMINATIONS
PDF
Mandates28/05/2020
DEMISSIONS, NOMINATIONS
PDF
Mandates10/09/2019
DEMISSIONS, NOMINATIONS
PDF
Mandates27/12/2018
DEMISSIONS, NOMINATIONS
PDF
Mandates20/09/2017
DEMISSIONS, NOMINATIONS
PDF

Similar companies

A company's peers, by sector and size, are included in the Business plan.

See the Business plan

Timeline

2024
Annual accounts 202468,9 k €↓
2023
Annual accounts 2023399,6 k €↑
2022
Annual accounts 2022289,5 k €↑
2021
Annual accounts 2021267,3 k €↓
2020
Annual accounts 2020295,7 k €↑
2019
Annual accounts 201940,5 k €↓
2018
Annual accounts 2018256,4 k €↓
2017
Annual accounts 2017400,3 k €↓
2016
Annual accounts 2016515,1 k €↑
2015
Annual accounts 2015154,6 k €↓
2014
Annual accounts 2014490,5 k €↑
2013
Annual accounts 2013426,6 k €↑
2012
Annual accounts 2012323,5 k €↓
2011
Annual accounts 2011355,2 k €↑
2010
Annual accounts 2010143,9 k €↓
2009
Annual accounts 2009224,2 k €↑
2008
Annual accounts 2008-146 k €↓
2006
Annual accounts 2006106 k €
23/12/1943
IncorporationPublic limited company

ARKOPHARMA BELUX

Overview

Identity

Financials

Valuation

Indicative valuation

Board of directors

Financials

Full financial information

Financial ratios

Annual accounts filings

Valuation

Indicative valuation

Directors & structure

Board of directors

Ownership and network

Publications

Belgian Official Gazette publications

Similar companies

Similar companies

Timeline

Timeline